News Classic

Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

9M 2024 financial information
+4% organic growth driven by Electrification
Set for a robust year

_PRESS RELEASE_

• Standard sales of €5,226 million in the first nine months of 2024, up +4.0% organically year on year and up +6.9% excluding Other activities
• Electrification businesses up +7.9% organically in the third quarter of 2024, reflecting early-bird strategic investments in the Generation & Transmission segment
• Strong adjusted backlog for Generation & Transmission, mainly subsea-driven, at €6.2 billion, up +19% compared to September 2023
• Expansion of manufacturing capacities through investments in onshore high-voltage and the production of low-carbon medium-voltage cables in France
• Strategic investment agreement in France to increase copper production and recycling capacity across Europe
• Ambitious Net-Zero 2050 climate targets approved by the Science Based Targets initiative
• Full-year 2024 guidance as updated in July 2024 confirmed
  • Adjusted EBITDA of between €750 and 800 million
  • Normalized Free Cash Flow of between €275 and 375 million
• Capital Markets Day to be held on November 13, 2024 in London and virtually, and US investors day on November 20, 2024 in New York City

~ ~ ~

Paris, October 30, 2024 – Nexans, a global leader in the design and manufacturing of cable systems to power the world, announces its financial information for the first nine months of 2024. Commenting on the Group’s highlights, Christopher Guérin, Nexans’ Chief Executive Officer, said:

“The first nine months of 2024 have laid strong foundations for a robust financial year. Our Electrification businesses continue to drive growth, up +7.9% organically in the third quarter of 2024, showcasing that early strategic investments in Generation & Transmission are already yielding benefits.

In order to reinforce the positioning of our electrification strategy and keep pace with increasing electricity demand, we have decided to invest €90 million in onshore high-voltage capacity at our French and Belgian plants and €15 million in the production of low-carbon medium-voltage cables in France. In addition, Nexans continues to lead the way in the circular economy with a strategic investment agreement at the Lens plant, enabling the recycling of over 80,000 metric tons per year.

As we look ahead, I am confident that our continued focus on performance and strategic execution will drive long-term value for all stakeholders. At our upcoming Capital Markets Day in November, where we will further outline the initiatives that will shape Nexans’ trajectory in the years to come.”

CONSOLIDATED SALES BY SEGMENT

9M AND Q3 2024 HIGHLIGHTS

In the first nine months of 2024, standard sales amounted to €5,226 million, up +4.0% compared to the same period of 2023 and up +6.9% excluding Other activities, which are being scaled down in line with the Group’s strategy. Third-quarter 2024 standard sales amounted to €1,680 million, down -0.5% organically and up +2.5% excluding Other activities compared to the third quarter of 2023.

The Electrification businesses (Generation & Transmission, Distribution and Usage) witnessed a strong organic sales increase of +12.1% in the first nine months thanks to (i) the ramp-up of the Halden plant (Norway) in the Generation & Transmission segment, (ii) ongoing positive demand driven by long-term trends in the Distribution segment, and (iii) a resilient Usage segment.

Non-electrification sales were down -3.8% in the first nine months of the year on account of a slowdown in the Automation business and a high base effect in the Auto-harnesses business. Other activities experienced a significant organic decrease of -14.2% compared to the first nine months of 2023 in line with the Group’s strategy.

SUSTAINABILITY

As a key player in electrification, Nexans is committed to not only driving the future of power, but also to integrating and promoting sustainability and safety across all its operations and activities. Aligned with its fundamental principles and commitments to achieving Net-Zero emissions by 2050, key initiatives were implemented during third-quarter 2024:

• Nexans’ ambitious Net-Zero 2050 climate objectives were approved by the Science Based Targets initiative, underscoring the company’s leadership in climate action.
• The Copper Mark, an esteemed label for responsible copper production, was awarded to Nexans’ foundries in Montreal, Canada, and Lens, France, highlighting the company’s dedication to ethical and sustainable practices.
• In a strategic move to bolster energy efficiency, Nexans partnered with Niehoff to launch an innovative rod breakdown line at the Lens facility in France, which is projected to cut energy usage by 25%. This translates into a substantial reduction of approximately 840 tons of CO₂ emissions annually.
• In line with its target of 100% decarbonized electricity consumption by 2030, Nexans inaugurated a 1.7 MW solar farm at its Cortaillod plant in Switzerland, with over 90% of the energy generated being used onsite.

9M 2024 STANDARD SALES PER SEGMENT

| GENERATION & TRANSMISSION (17% OF TOTAL STANDARD SALES)

Generation & Transmission standard sales came in at €899 million in the first nine months of 2024, up +54.3% organically compared to the first nine months of 2023, propelled by the ramp up of new capacity at the Halden plant (Norway). In the third quarter of 2024, sales were up +36.2% organically compared to the third quarter of 2023, reflecting notably robust installation campaigns, Great Sea Interconnector execution and contributions from Inspection, Maintenance and Repair (IMR) works.

Customer activity remained robust, and in line with its risk-reward selectivity approach, the segment’s adjusted backlog reached €6.2 billion at September 30, 2024, up +19% compared to September 30, 2023. In the third quarter, Nexans secured the final contract for the pioneering electrical transmission link from the Orkney Islands in Scotland. Additionally, a definitive agreement was reached between Greece and Cyprus for the ambitious Great Sea Interconnector at the end of September. This key development represents a crucial step forward for the project, and Nexans is now anticipating the final notice to proceed with the contract.

During the third quarter, the Group unveiled a strategic €90 million investment at its facilities in France and Belgium. This investment will increase the production of advanced 525kV onshore cables meeting the requirements of the TenneT frame agreement. Progress continues apace on Nexans Electra, the company’s third cable-laying vessel. This state-of-the-art vessel is set to markedly increase the company’s installation capacity, effectively addressing the business’s expanding backlog.

| DISTRIBUTION (18% OF TOTAL STANDARD SALES)

Distribution sales amounted to €923 million at standard metal prices in the first nine months of 2024, up +1.6% organically, compared to the first nine months of 2023.

Europe has seen an uptick, thanks to the establishment of new frame agreements and a surge in renewable energy projects. This progress has been achieved notwithstanding the temporary dip in activity due to the consolidation of manufacturing operations in Finland during the third quarter. In France, the Group invested €15 million in late August to increase its capabilities in producing low-carbon medium-voltage cables in order to support growth in electrification requirements in France and in Western Europe. Additionally, the Group pioneered a cutting-edge solar power solution in France, designed to support the photovoltaic sector with a sustainable, low-carbon alternative.

The Asia Pacific region has witnessed a rebound primarily fueled by substantial investments in renewable energy and grid enhancement projects, especially in Australia and New Zealand.

In the Americas, the underlying market conditions have continued to exhibit strength. Despite this, the growth trajectory has moderated slightly, influenced by destocking and the timing of substantial orders.

| USAGE (29% OF TOTAL STANDARD SALES)

Usage sales amounted to €1,522 million at standard metal prices in the first nine months of 2024, up +0.5% organically compared with the first nine months of 2023.

In North America (Canada), solid demand in industrial markets during Q3 2024 supported the Group’s growth. While Europe faced headwinds with lower volumes and destocking in certain markets, South America saw strong demand in Brazil and Chile, while destocking in Columbia. In Africa, a robust recovery in Morocco offset the subdued demand in Turkey.

In a strategic move to fortify its commitment to 30% recycled copper in its products by 2030, Nexans launched CableLoop, an exclusive cable recycling and recovery service in France and across Europe. CableLoop is a pioneering, end-to-end solution that facilitates the collection of installation cable off-cuts in distributors’ networks at the Group’s recycling centers. Here, these materials are transformed into high-quality recycled raw materials, exemplifying the Group’s dedication to circular economy principles.

The sales figures reflect the strategic acquisitions of La Triveneta Cavi as of June 1, 2024, and Reka Cables since April 2023. These acquisitions are integral to Nexans’ Electrification strategy, expanding the Group’s capabilities in key regions.

| NON-ELECTRIFICATION (Industry & Solutions) (25% OF TOTAL STANDARD SALES)

In the Industry & Solutions segment, standard sales for 9M 2024 amounted to €1,294 million, reflecting an organic year-on-year decline of -3.8%. This was primarily attributed to a slowdown in Automation, which was partially offset by robust growth in the Shipbuilding, Nuclear and Rolling Stock markets. Auto-harnesses market remained resilient despite a high base effect from last year.

| OTHER ACTIVITIES (11% OF TOTAL STANDARD SALES)

The Other Activities segment – corresponding for the most part to copper wire sales and corporate costs that cannot be allocated to other segments – reported standard sales of €588 million in 9M 2024. Standard sales were down -14.2% organically year-on-year, mainly linked to the Group’s strategy to reduce copper wire external sales through tolling agreements in order to mitigate their dilutive effect.

2024 OUTLOOK

As the world continues to embrace electrification, Nexans is well-positioned to harness buoyant market demand, supported by global megatrends and the Company’s commitment to delivering value-added solutions. Nexans’ Generation & Transmission segment boasts a strong risk-reward adjusted backlog, ensuring solid visibility. The Group is poised to reap benefits from the expanded capacity of the Halden plant in Norway, positioning Nexans to meet the growing global demand for high-voltage solutions. Looking ahead, the Generation & Transmission business is on a trajectory of gradual improvement. This progress is contingent upon the successful execution of projects and the completion of legacy contracts. The Distribution market is entering a significant hyper cycle of investment, presenting Nexans with opportunities for growth and enhanced profitability. Despite weak demand in certain geographies within the construction sector, Nexans’ Usage segment remains resilient, with strategic initiatives in place to mitigate the impact of these macroeconomic conditions.

The Group expects to achieve the following targets which were upgraded in July, excluding the impact of any non-closed acquisitions and divestments:

• Adjusted EBITDA of between €750 and €800 million (€670 – €730 million previously);
• Normalized Free Cash Flow of between €275 and €375 million (€200 – €300 million previously).

Nexans reaffirms its commitment to the 2021 Capital Markets Day targets and will continue to execute its strategic roadmap and priorities.

SIGNIFICANT EVENTS SINCE THE END OF SEPTEMBER

October 22, 2024 – Nexans signed a strategic investment agreement in France to increase its copper production and recycling capacity across Europe. With an investment of over €90 million, wire rod production capacity will increase by over 50% at the Lens plant, boosting its copper scrap recycling capacity to manage up to 80,000 metric tons per year.

The third-quarter 2024 press release and presentation slides are available in the Investor Relations Results section at Nexans – Financial results.

A conference call is scheduled today at 9:45 a.m. CET. Please find below the access details:

Webcast
https://channel.royalcast.com/landingpage/nexans/20241030_1/

Audio dial-in

• International switchboard: +44 (0) 33 0551 0200
• France: +33 (0) 1 70 37 71 66
• United Kingdom: +44 (0) 33 0551 0200
• United States: +1 786 697 3501

Confirmation code: Nexans

~ ~ ~

Financial calendar

November 13, 2024:         Capital Markets Day, London and virtually
November 20, 2024:         US investors day, New York City
February 19, 2025:         Full-year 2024 earnings

About Nexans

For over a century, Nexans has played a crucial role in the electrification of the planet and is committed to electrifying the future. With approximately 28,500 people in 41 countries, the Group is paving the way to a new world of safe, sustainable and decarbonized electricity that is accessible to everyone. In 2023, Nexans generated €6.5 billion in standard sales. The Group is a leader in the design and manufacturing of cable systems and services across four main business areas: Generation & Transmission, Distribution, Usage and Industry & Solutions. Nexans was the first company in its industry to create a Foundation supporting sustainable initiatives, bringing access to energy to disadvantaged communities worldwide. The Group is recognized on the CDP Climate Change A List as a global leader on climate action and has committed to Net-Zero emissions by 2050 aligned with the Science Based Targets initiative (SBTi).

Nexans. Electrify the Future.

Nexans is listed on Euronext Paris, compartment A.
For more information, please visit www.nexans.com

Contacts

NB: Any discrepancies are due to rounding

This press release contains forward-looking statements which are subject to various expected or unexpected risks and uncertainties that could have a material impact on the Company’s future performance.

Readers are invited to visit the Group’s website where they can view and download the Universal Registration Document, which include a description of the Group’s risk factors. 

• Nexans_Third quarter 2024 Press release_Final

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules

MEDIA RELEASE

• Strong third-quarter biosimilars growth of 37% in constant currencies from existing portfolio and recent launches
• Generics growth acceleration driven by Europe
• Third-quarter net sales¹ of USD 2.6 billion, up 12% in constant currencies (up 11% in USD)
• Nine-month net sales of USD 7.6 billion, up 9% in constant currencies (up 8% in USD)
• Net sales growth guidance increased to high-single digit in constant currencies (from mid- to high-single digit) and core EBITDA margin² guidance of around 20% confirmed

Basel, October 30, 2024 – Sandoz SDZNY, the global leader in generic and biosimilar medicines, today announced net sales for the third quarter and nine months ended September 30, 2024. For the third quarter, net sales were USD 2.6 billion, an increase of 12% in constant currencies compared to the same quarter of the prior year. For the first nine months of 2024, net sales were USD 7.6 billion, an increase of 9% in constant currencies compared to the prior year.

Richard Saynor, Chief Executive Officer of Sandoz, said: “We remain focused on execution, meeting key milestones in our biosimilars business and progressing on our journey as a standalone company. In recent months, we received approval for Pyzchiva® and Enzeevu™ in the US, launched Pyzchiva® in Europe and see continued strong uptake of Hyrimoz® in the US.

“Net sales growth was achieved across generics and biosimilars, with generics accelerating in the third quarter and strong double-digit biosimilars growth in both the third quarter and first nine months. Additionally, all three regions contributed to this strong performance. We expect momentum in our business to continue, driving margin expansion through favorable product mix and leveraging our cost base. We have further advanced on our path to simplifying our business, including progression on the transformation program we launched earlier this year.”

THIRD-QUARTER AND NINE-MONTH SALES

Net sales for the third quarter were USD 2.6 billion, up 12% in constant currencies, compared to the third quarter of 2023. Volume contributed 13 percentage points of growth. This was partially offset by price erosion of 1 percentage point. Biosimilars were the key driver of growth in the quarter, while generics experienced solid demand. Growth accelerated in both businesses.

Net sales for the first nine months of 2024 were USD 7.6 billion, up 9% in constant currencies compared to prior year. Volume contributed 11 percentage points of growth. This was partially offset by price erosion of 2 percentage points. The growth was primarily driven by biosimilars, with strong demand for both the base business and new in-market organic and acquired products in the US.

Net sales by business

 ^{*constant currencies}

Generics overview
Net sales for the third quarter were USD 1.9 billion, up 4% in constant currencies, compared to the third quarter of 2023. Net sales for the first nine months were USD 5.6 billion, up 2% in constant currencies versus prior year.

Growth in the Europe region accelerated in the third quarter, mainly driven by recent launches. The momentum continued in the International region, aided by demand for the antifungal agent Mycamine® and favorable pricing dynamics, partly offset by the divestment of the Chinese business. North America declined due to timing of new launches in the US.

Biosimilars overview
Net sales for the third quarter were USD 741 million, up 37% in constant currencies, compared to the third quarter of 2023. Net sales for the first nine months were USD 2.1 billion, up 32% in constant currencies versus prior year.

The strong double-digit biosimilars growth reflects the uptake of Hyrimoz® (adalimumab) in the US, the acquisition of Cimerli® (ranibizumab), the continued strong demand for our first-ever biosimilar, Omnitrope® (somatropin), and the launches of Tyruko® (natalizumab) and Pyzchiva® (ustekinumab) in Europe.

Net sales by region

Europe overview
Net sales for the third quarter were USD 1.4 billion, up 12% in constant currencies, compared to the third quarter of 2023. Net sales for the first nine months were USD 4.0 billion, up 6% in constant currencies versus prior year.

Strong growth in biosimilars continues, led by demand for Omnitrope® and the contribution from the recent launches of Tyruko® and Pyzchiva®. Generics momentum accelerated in the third quarter, driven by recent launches and the lapping of the strong prior-year comparison in the first half.

North America overview
Net sales for the third quarter were USD 598 million, up 18% in constant currencies, compared to the third quarter of 2023. Net sales for the first nine months were USD 1.7 billion, up 15% in constant currencies versus prior year.

Growth was driven by the ongoing uptake of Hyrimoz® in the US, the acquisition of Cimerli®, share gain of Omnitrope® in the US and the launch of Wyost®/Jubbonti® in Canada. This was partly offset by a decline in generics sales due to the timing of new launches in the US.

International overview
Net sales for the third quarter were USD 635 million, up 8% in constant currencies, compared to the third quarter of 2023. Net sales for the first nine months were USD 1.9 billion, up 9% in constant currencies versus prior year.

This was primarily a result of strong volume growth across both generics and biosimilars, contribution from the acquisition of Mycamine® in the prior year, favorable price dynamics and recent launches, partly offset by the divestment of the Chinese business in the second quarter.

GUIDANCE 2024

On the back of strong momentum in its biosimilars business and solid generics demand, the company is increasing its full-year 2024 net sales guidance to high-single digit growth in constant currencies versus prior year (from mid- to high-single digit) and is confirming its core EBITDA margin guidance of around 20%.

THIRD-QUARTER STRATEGIC MILESTONES

Sandoz continued to execute on its strategy and passed additional milestones in its biosimilars portfolio.
On July 1, the company announced the US FDA approval of biosimilar Pyzchiva® for all indications of the reference medicine. The company intends to launch Pyzchiva® in the US among the first wave of ustekinumab biosimilars in February 2025.

On July 25, Sandoz announced the launch of biosimilar Pyzchiva® across Europe to treat chronic inflammatory diseases. Pyzchiva® was the first biosimilar to launch in Europe with all reference medicine strengths, including an initiation dose for Crohn’s disease.

On August 12, Sandoz received FDA approval for Enzeevu™ to treat neovascular age-related macular degeneration. This approval further enhances the company’s leading US ophthalmology portfolio and increases access for patients. Launch timing will be dependent on several factors, including the progress and outcome of pending or potential litigation or any potential settlements.

KEY LINKS

Webcast – Live at 9am CET
Analyst call presentation
Analyst consensus

DISCLAIMER

This media release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.
This media release includes non-IFRS financial measures as defined by Sandoz. An explanation of non-IFRS measures can be found in the Supplementary financial information of the Half-Year Report 2024.

ABOUT SANDOZ

Sandoz (SDZSDZNY is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 800 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,500 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2023, Sandoz recorded net sales of USD 9.6 billion.

CONTACTS

SUPPORTING FINANCIAL INFORMATION

Quarterly net sales

2024

2023

^{¹ Net sales in this document refer systematically to net sales to third parties. In the first nine months of 2023, third-party sales excluded sales to our former parent. Post spin-off, sales to our former parent are reported as third-party sales.
² An explanation of non-IFRS measures can be found in the Supplementary financial information of the Half-Year Report 2024}

• 241030_Q3 and 9M Sales 2024_ Media Release.pdf

Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

GOTHENBURG, Sweden, Oct. 30, 2024 /PRNewswire/ —

Q3 2024
Net sales: SEK 23,692 million (25,771)
Organic growth: −4.4% (−0.6%), driven by lower market demand across most regions and industries.
Adjusted operating profit: SEK 2,821 million (2,956). Continued strong price/mix contribution, driven by pricing actions and active portfolio management, as well as good cost control which largely offset the lower volumes and currency headwind.
Adjusted operating margin: 11.9% (11.5%)
Net cash flow from operations: SEK 3,576 million (3,435)

Rickard Gustafson, President and CEO:

“We are pleased to report a continued solid margin development, representing a year-over-year improvement, despite declining volumes in the prevailing weak market environment and significant currency headwinds. We continue our strategic execution creating an even stronger SKF, with the initiated separation of our Automotive business as a key component.”

Solid margin and strong cash flow

The weak market conditions prevailed globally during the third quarter, which also was reflected in multiple leading external macro indicators. Our organic sales declined by -4.4%, driven in particular by a weak demand in China and within Automotive, especially towards the end of the quarter. On the other hand, our sales in India and within Aerospace were solid.

Our adjusted operating margin, on the other hand, improved year-over-year and came in just shy of 12%, another proof point of our ability to better adapt to volatile market conditions. Our cost management and robust price/mix actions have effectively offset lower sales volumes, a significant negative currency impact and ongoing regionalization of our manufacturing footprint. We continue to work hard on cost out activities to mitigate potential short-term impact on our cost efficiency from the current lower volume environment.

Our ability to uphold solid earnings also contributed to a strong cash flow from operations of SEK 3.6 billion.

Unlocking value by separating the Automotive business

The announced initiated separation of our Automotive segment follows our strategy to create a separate Automotive business. There is a strong strategic rationale for the separation since Industrial and Automotive are two business segments with different business logics. By establishing two fit-for-purpose independent companies, we expect to unlock long-term value and to accelerate profitable growth in both businesses.

Since the announcement of the separation in mid-September, we have kick-started the separation planning and formed a dedicated project organization with the aim of listing the Automotive business in the first half of 2026. We intend to host a Capital Markets Day in Q4 2025 to share more information on the ambitions for both our Industrial and Automotive businesses.

Strategic portfolio management to build a stronger SKF

We continue to actively work with our portfolio to create a more focused and resilient SKF. I’m pleased that we have signed a contract to divest our ring and seal operation in Hanover, USA, which is a non-strategic asset for our Aerospace business, representing annual sales of approximately SEK 700 million, for a total value of approximately SEK 2.3 billion. Aerospace will remain one of our largest customer industries, representing total annual sales of approximately SEK 6 billion, corresponding to 9% of industrial net sales after the divestment. We will continue to invest and strengthen our position in core Aerospace segments related to the aeroengine and aerostructure bearing offers to optimize our business potential.

With our strategy and decentralized operating model being well implemented, we are now in a position to also gradually accelerate profitable growth through smaller bolt-on acquisitions. As an example, the announced acquisition of John Sample Group is margin accretive and further strengthens our lubrication offering and position in the expansive India and Southeast Asia region.

I would like to express my sincere gratitude to our employees for their contributions to achieving solid margin and strong cash flow, despite the weak demand environment, and a continued high pace in our strategic execution.

Outlook

We expect to see continued market and geopolitical volatility, and the business is prepared to tackle different scenarios. For the fourth quarter of 2024, we expect a mid-single-digit organic sales decline, year-over-year. For the full year, we expect a mid-single-digit organic sales decline, compared to 2023.”

Outlook and Guidance

Outlook

• Q4 2024: We expect a mid-single-digit organic sales decline, year-over-year.
• FY 2024: We expect a mid-single-digit organic sales decline, year-over-year.

Guidance Q4 2024

• Currency impact on the operating profit is expected to be around SEK 250 million negative compared with the fourth quarter 2023, based on exchange rates per 30 September 2024.

Guidance FY 2024

• Tax level excluding effects related to divested businesses: around 26%.
• Additions to property, plant and equipment: around SEK 5 billion.

A webcast will be held on 30 October 2024 at 08:00 (CET):
Sweden +46 (0)8 5051 0031
UK / International +44 (0)207 107 0613
https://investors.skf.com/en

Aktiebolaget SKF
     (publ)

The financial information in this press release contains inside information that AB SKF is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out below on 30 October 2024 at 07.00 CET.

For further information, please contact:
PRESS: Carl Bjernstam, Head of Media Relations
tel: 46 31-337 2517; mobile: 46 722-201 893; e-mail: carl.bjernstam@skf.com

INVESTOR RELATIONS: Sophie Arnius, Head of Investor Relations
tel: 46 31-337 8072; mobile: 46 705-908 072; e-mail: sophie.arnius@skf.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/skf/r/skf-interim-report-q3-2024–solid-margin-and-strong-cash-flow-in-weak-markets,c4058563

The following files are available for download:

View original content:https://www.prnewswire.com/news-releases/skf-interim-report-q3-2024-solid-margin-and-strong-cash-flow-in-weak-markets-302291134.html

SOURCE SKF